Who Pays My Doctor?

Healthcare provider profile · identity verified

John Joseph Miller, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · EXETER, NH · NPI 1841307527

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Joseph Miller, M.D. received $636,924.92 in general payments during 2025 across 583 reported records.

Axsome Therapeutics, Inc. accounted for 22.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 10 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Rexulti.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$636,924.92

583 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $143,624.1422.6%1162025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $139,328.4121.9%1322025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $122,391.4919.2%872025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $107,247.3816.8%1112025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $80,691.1112.7%902025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $31,408.054.9%232025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $12,017.481.9%192025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $141.240.0%32025
Alkermes, Inc. Unresolved — no canonical attribution shown $63.530.0%12025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $12.090.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$412,418.00110
Honoraria$126,569.5023
Travel and Lodging$49,009.81242
Consulting Fee$34,548.0010
Food and Beverage$14,318.61197
Education$61.001

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $143,624.14 116 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $124,750.41 126 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $122,391.49 87 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $107,247.38 111 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. $80,787.41 92 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $31,363.05 22 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC $12,029.57 20 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $63.53 1 2025
Source payment records
ARISTADA INITIO
Normalized: aristada initio		 Drug Alkermes, Inc. $63.53 1 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $45.00 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
INGREZZA
ingrezza		 2025 Ingrezza 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
REXULTI
rexulti		 2025 Rexulti 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Neurocrine BioSciences, Inc.
Exact reporting entity; no affiliate inference		 2025 INGREZZA
open payments reported associated product		 CMS Open Payments — General Payments
126456 supporting records · 27390 recipient NPIs · example record 1242766729 		Ingrezza · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
160756 supporting records · 46288 recipient NPIs · example record 1227267708 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
1463 supporting records · 1088 recipient NPIs · example record 1225319865 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
ClonazepamClonazepam15917
GabapentinGabapentin10417
Trazodone HclTrazodone Hcl9016
LorazepamLorazepam8112
Sertraline HclSertraline Hcl7316
Quetiapine FumarateQuetiapine Fumarate52suppressed
Bupropion XlBupropion Hcl51suppressed
DiazepamDiazepam36suppressed
Fluoxetine HclFluoxetine Hcl29suppressed
Ziprasidone HclZiprasidone Hcl27suppressed
Escitalopram OxalateEscitalopram Oxalate24suppressed
Quetiapine Fumarate ErQuetiapine Fumarate24suppressed
VraylarCariprazine Hcl24suppressed
Lithium CarbonateLithium Carbonate23suppressed
Lurasidone HclLurasidone Hcl20suppressed
Citalopram HbrCitalopram Hydrobromide18suppressed
Buspirone HclBuspirone Hcl17suppressed
Venlafaxine Hcl ErVenlafaxine Hcl15suppressed
RisperidoneRisperidone14suppressed
AripiprazoleAripiprazole13suppressed
Risperdal ConstaRisperidone Microspheres13suppressed
AlprazolamAlprazolam12suppressed
Hydroxyzine HclHydroxyzine Hcl12suppressed
IngrezzaValbenazine Tosylate12suppressed
LamotrigineLamotrigine12suppressed
Nortriptyline HclNortriptyline Hcl12suppressed
PregabalinPregabalin12suppressed
Tranylcypromine SulfateTranylcypromine Sulfate12suppressed
Bupropion HclBupropion Hcl11suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11suppressed
RexultiBrexpiprazole11suppressed
ZyprexaOlanzapine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $636,924.92 · 583 records Axsome Therapeutics, Inc. ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, INGREZZA, REXULTI, SPRAVATO, UZEDY 3 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error